Premium
L‐citrulline provides a novel strategy for treating chronic pulmonary hypertension in newborn infants
Author(s) -
Fike Candice D.,
Summar Marshall,
Aschner Judy L.
Publication year - 2014
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.12707
Subject(s) - medicine , citrulline , pulmonary hypertension , nitric oxide , persistent pulmonary hypertension , arginine , chronic hypertension , intensive care medicine , cardiology , biochemistry , amino acid , chemistry , pregnancy , biology , preeclampsia , genetics
Effective therapies are urgently needed for infants with forms of pulmonary hypertension that develop or persist beyond the first week of life. The L‐arginine nitric oxide ( NO ) precursor, L‐citrulline, improves NO signalling and ameliorates pulmonary hypertension in newborn animals. In vitro studies demonstrate that manipulating L‐citrulline transport alters NO production. Conclusion Strategies that increase the supply and transport of L‐citrulline merit pursuit as novel approaches to managing infants with chronic, progressive pulmonary hypertension.